11 results about "Cytokine activity" patented technology

The application relates to cytokine receptor agonists comprising: i) a first PD-1 binding domain capable of binding a first epitope on PD-1, ii) a second PD-1 binding domain capable of binding a second epitope on PD-1, iii) an IL2Rγ binding domain, iv) an IL2Rβ binding domain, and v) an Fc region, and wherein the first and second PD-1 binding domains do not compete for binding on PD-1. The PD1-binding domains simultaneously bind the PD-1 and the IL-2 receptor-binding domains bind subunits of an IL-2 receptor complex. Biparatopic assembly of the IL-2 receptor-binding domains in the presence of PD-1 allows to selectively activate IL-2 receptors and effectively mimic cytokine activity in a targeted manner.

The invention discloses an interferon-gamma cytokine activity detection method and application thereof. The interferon-gamma cytokine activity detection method comprises the following steps: (1) cell planking: inoculating HT29 cells into a porous plate according to the density of 3000-5000 cells per pore for pre-culture; (2) sample adding treatment: adding an interferon-gamma recombinant protein working solution which is diluted in a gradient manner into each hole in the step (1), continuously culturing after sample adding, and enabling the total culture time of the action of cells and interferon-gamma to be 24-96 hours; (3) activity detection: after culture is finished, determining cell activity by adopting a CCK-8 method; and (4) data processing: calculating the half effective concentration value of the interferon-gamma according to the measurement result. The invention provides a systematic, accurate and repeatable interferon-gamma cytokine activity detection method, a synergistic action mechanism of cell density and culture time is disclosed for the first time, and a detection result is highly consistent with an international authority standard database.

Disclosed are glycan compounds and their use for treating or inhibiting the development of inflammatory conditions or conditions associated with cytokine activity, such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS) and dermatitis.

To provide retroviral and lentiviral vectors.SOLUTION: The invention provides a retroviral or lentiviral vector having a viral envelope comprising: (i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T cell activating transmembrane protein comprising a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T cell activating transmembrane protein is not part of the viral envelope glycoprotein. When cells such as natural killer cells are transduced with such viral vectors, they are simultaneously activated by the mitogenic T cell activating transmembrane protein and / or the cytokine-based T cell activating transmembrane protein.SELECTED DRAWING: None

The disclosure relates to methods for redirecting an active form of an endogenous cytokine to a target cell or target tissue of interest in a biological system or subject in need thereof by administering a multi-specific binding molecule comprising (a) a binding domain that specifically binds to an active form of a cytokine and (b) a binding domain that specifically binds to an epitope on a molecule that is a marker on a target cell or tissue, wherein the multi-specific binding molecule, when bound to the cytokine, does not block or only partially blocks, the ability of the cytokine to bind to and agonize a cognate receptor for the cytokine.

The invention discloses a stably transfected cell strain for detecting activity of Wnt and / or R-spondin family cytokines as well as a construction method and application of the stably transfected cell strain, and belongs to the technical field of biological medicines. Comprising the following steps: preparing target plasmids: respectively connecting a SuperTOP sequence and a SuperFOP sequence to two different expression plasmids, and respectively connecting luciferase reporter genes to obtain a target plasmid A and a target plasmid B; respectively transfecting the target plasmid A and the target plasmid B into human kidney epithelial cells, culturing in a puromycin-containing culture medium, and sorting positive cells according to labeled fluorescence GFP (Green Fluorescent Protein) to obtain stably transfected cells A and stably transfected cells B. The method has the advantages that activity detection of Wnt family and R-spondin family cell factors is carried out on stably transfected cells, operation is simple, the detection period is shortened by 25%, sensitivity is improved by at least 50%, and the method has high application prospects and economic value.

Disclosed herein are stable peptide antagonists based on the consensus yc-subunit binding site to inhibit the activity of yc-cytokines. Such peptide antagonists are capable of inhibiting the activity of multiple yc-cytokine family members. The yc-family cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of yc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.

The application relates to antigen binding molecules comprising a pair of biparatopic target-binding domains, a pair of cytokine receptor-binding domains and an Fc domain, wherein the target-binding domains simultaneously bind the target antigen and the cytokine receptor-binding domains bind subunits of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor-binding domains in presence of the target antigen allows to selectively activate cytokine receptors and effectively mimic cytokine activity in a targeted manner.

A composition of matter comprising at least one fusion polypeptide which comprises a targeting moiety which binds a marker of a myeloid-derived suppressor cell (MDSC) attached to an immune cell-activating cytokine, wherein said immune cell-activating cytokine is masked by a masking agent, such that when said at least one fusion polypeptide is in a vicinity of an MSDC. said masking agent unmasks said immune cell -activating cytokine via an activity of an MSDC- specific protease so as to allow cytokine activity of said immune cell-activating cytokine. Also provided are methods and uses of such a composition for the treatment of cancer.

The application relates to pairs of antigen binding molecules, each molecule comprising a target-binding domain, a cytokine receptor-binding domain and an Fc domain, wherein the target-binding domains simultaneously bind the target antigen and the cytokine receptor-binding domains bind subunits of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor-binding domains in presence of the target antigen allows to selectively activate a cytokine receptor and effectively mimic cytokine activity in a targeted manner.

Cytokine receptor agonist The application relates to cytokine receptor agonists comprising: i) a first PD-1 binding domain capable of binding a first epitope on PD-1, ii) a second PD-1 binding domain capable of binding a second epitope on PD-1, iii) an IL2Rγ binding domain, iv) an IL2Rβ binding domain, v) an IL7Rα binding domain, and vi) an Fc region, and wherein the first and second PD-1 binding domains do not compete for binding on PD- 1. The PD1-binding domains simultaneously bind the PD-1 and the cytokine receptor-binding domains bind subunits of cytokine receptor complexes. Biparatopic assembly of the cytokine receptor-binding domains in the presence of PD-1 allows to selectively activate cytokine receptors and effectively mimic cytokine activity in a targeted manner.